Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hMSCs for Anthracycline-Associated Cardiomyopathy
NCT02408432Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2016
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MSV alogénicas in cardiomyopathy and heart failure (HF) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events of intravenous injection of human mesenchymal stem cells (hMSCs) at 6 months. Started Jan 2016; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
cardiomyopathyheart failure (HF)
Beyond the preview
Go deeper on NCT02408432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408432.